Amanta Healthcare Limited Files DRHP With SEBI For Fresh Issue of 1.25 Crore Equity Shares up to Rs1,25,00,000 and each share has a price of Rs 10. This has only fresh issues.
Deployments of funds: 70 crores have been considered for equipment, plant, and machinery. 30 crore would be used for new small-volume parenteral(SVP), while the rest of the funds are for general purposes.
The company’s promoters and directors include Bhavesh Patel, Vishal Patel, Jayshreeben Patel, and Jitendrakumar Patel, moreover Beeline Capital Advisors is the main manager for Amanta Healthcare’s IPO.
Amanta Healthcare Limited is a pharmaceutical company that develops, makes, and sells sterile liquid products and was founded in 1998. this company has exported its products to over 19 countries, holding 113 active international product registrations. Amanta sells over 45 generic medicines in India and works with other companies to make products in large amounts.
This company has a satisfactory revenue of 280.34 crore in FY 2024, which has soared around 8.2% compared to the previous year. Total asset is -6.71 %, fixed assets are -4.54% and current asset is approx 0.87%.
Amanta Healthcare IPO Prospectus:
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | To be Updated Soon |
Amanta Healthcare Company Financial Report
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax |
| 2022 | ₹226.27 | ₹171.81 | ₹53.88 |
| 2023 | ₹262.70 | ₹206.39 | ₹2.11 |
| 2024 | ₹281.61 | ₹222.85 | ₹3.62 |
Amanta Healthcare IPO Valuation – FY2024
Amanta Healthcare IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| Earning Per Share (EPS): | ₹1.35 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 5.48% |
| Net Asset Value (NAV): | ₹24.71 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Denis Chem Lab Limited | 8.04 | 18.76 | 13.88 | 57.91 | 169.21 Cr. |
Objects of the Issue
- Funding capital expenditure requirements for civil construction work and towards purchase of equipment,
- plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat;
- Funding capital expenditure requirements towards purchase of equipment, plant and machinery for setting up
new manufacturing line for Small Volume Parenteral (“SVP”) at Hariyala, Kheda, Gujarat; and - General corporate purposes.
IPO Lead Managers aka Merchant Bankers
- Beeline Capital Advisors Private Limited
